Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease in which the immune system mistakenly attacks the synovial membrane of the joints. Joint pain, morning stiffness, swelling and progressive joint destruction significantly impair the quality of life of millions of people. Alongside pharmacological treatment with DMARDs, biologics and NSAIDs, omega-3 has been investigated in rheumatology as a complementary measure for over three decades. The scientific evidence is now robust: several meta-analyses show that omega-3 supplementation reduces joint pain, decreases morning stiffness and can reduce the need for analgesics in RA. This page provides a comprehensive overview of the evidence — with specific study details, dosage data and practical limitations.
What is rheumatoid arthritis — and why might omega-3 help?
Rheumatoid arthritis is not a degenerative disease like osteoarthritis, but an autoimmune condition. The immune system produces antibodies against the body's own joint structures — primarily against the synovial membrane. The resulting chronic inflammation causes the release of cytokines such as TNF-alpha, IL-1 and IL-6, which cause joint pain and damage cartilage and bone over time.
The connection to omega-3
Since omega-3 fatty acids demonstrably reduce inflammatory markers such as TNF-alpha and IL-6 (as described on the page Omega-3 and inflammation), it is plausible that they may also play a role in RA. EPA additionally inhibits the arachidonic acid cascade, from which pro-inflammatory prostaglandins and leukotrienes directly involved in joint pain development are derived. These mechanisms are well documented in cell culture and animal studies; their clinical translatability to humans has been investigated in numerous randomised controlled trials.
Important terms
Morning stiffness is a cardinal symptom of RA: after waking, affected joints are stiff and painful for at least 30–60 minutes. The duration of morning stiffness is a clinical marker of inflammatory activity. NSAID consumption (non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen, diclofenac) is a frequent secondary endpoint in RA studies: if patients need fewer analgesics, this indicates better symptom control.
RA vs. osteoarthritis: an important distinction
Rheumatoid arthritis (RA) is an autoimmune condition with chronic joint inflammation — typically affecting the small joints of both hands symmetrically. Osteoarthritis, by contrast, is a degenerative disease caused by cartilage wear affecting primarily large, weight-bearing joints. The evidence for omega-3 is better supported in RA than in osteoarthritis. The mechanisms differ: in RA, the anti-inflammatory action is the decisive factor; in osteoarthritis, cartilage-protective mechanisms are relevant.
Scientific evidence: what do meta-analyses show?
The evidence on omega-3 and rheumatoid arthritis is one of the most thoroughly researched areas in omega-3 research. Three major meta-analyses and systematic reviews are particularly relevant:
Lee YH et al.: 10 RCTs — significant pain reduction and NSAID sparing
This meta-analysis by Lee YH, Bae SC and Song GG evaluated 10 randomised controlled trials on omega-3 in rheumatoid arthritis. Key finding: at a dose of at least 2.7 g EPA+DHA per day for at least 3 months, a significant reduction in joint pain was observed (SMD −0.518; 95% CI −0.915 to −0.121; P = 0.011), along with reduced morning stiffness, fewer tender joints and — particularly clinically relevant — a significant reduction in NSAID consumption.
Abdulrazaq et al.: 18 RCTs, 1,143 patients — greatest effect at 3–6 g/day
This systematic review by Abdulrazaq M, Innes JK and Calder PC evaluated 18 randomised trials with a total of 1,143 patients. In 10 of the 18 studies, a statistically significant reduction in pain in rheumatoid arthritis was observed. The authors identified a dose dependency: doses of 3–6 g EPA+DHA per day showed the greatest effect. The authors' conclusion: omega-3 has a therapeutic role in RA-associated pain and could be integrated into clinical practice.
Chronic pain: SMD = −0.55, at 6 months SMD = −0.83
This current meta-analysis investigated omega-3 and chronic pain — including arthritis patients. Overall result: SMD = −0.55 (95% CI −0.76 to −0.34) — a moderate, statistically and clinically significant pain reduction. Particularly informative was the temporal analysis: after 1 month, effect size was SMD = −0.27 (small); after 3 months, SMD = −0.55 (moderate); after 6 months, SMD = −0.83 (large). Efficacy increases with duration of intake — supporting the clinical recommendation for prolonged use.
What endpoints were measured in RA studies?
Studies on omega-3 in rheumatoid arthritis used a broad spectrum of clinical endpoints:
| Endpoint | Measurement method | Result in meta-analyses |
|---|---|---|
| Joint pain | VAS (visual analogue scale 0–100), NRS | Significant reduction with ≥2.7 g/day |
| Morning stiffness (duration) | Minutes after waking | Significant reduction |
| Number of tender joints | Joint count (28-joint score) | Reduction in several studies |
| Number of swollen joints | Swollen joint count | Variable results |
| NSAID consumption | Dose in mg/day or frequency | Significant reduction (Lee 2012) |
| DAS28 | Disease Activity Score (28 joints) | Reduction in individual studies |
| Inflammatory markers (CRP, ESR) | Laboratory values | CRP reduction in umbrella meta-analysis |
NSAID reduction: the most clinically important finding?
From a clinical perspective, the possibility of reducing NSAIDs is one of the most significant observations in omega-3 RA studies. NSAIDs are highly effective analgesics, but their long-term use carries considerable risks: gastrointestinal bleeding and ulcers, cardiovascular risks (especially with COX-2 inhibitors) and renal damage in pre-existing kidney impairment.
If omega-3 allows the NSAID dose to be reduced or taken less frequently, this has a direct clinical benefit — not only for symptom control, but also for reducing drug side effects. The Lee et al. (2012) meta-analysis showed this NSAID-sparing effect in a statistically significant manner.
Omega-3 and NSAIDs: complementary, not competing
Omega-3 is not a substitute for NSAIDs or other RA medications. The idea is to combine both approaches: omega-3 addresses the inflammatory basis, NSAIDs control acute pain. If omega-3 slightly reduces inflammatory activity, perhaps a lower NSAID dose may suffice to control symptoms. This is a complementary approach that rheumatologists are increasingly incorporating into dietary counselling.
Quality of studies and limitations
The meta-analyses are methodologically solid, but have some limitations important for a realistic assessment:
Study heterogeneity
Included studies differ considerably in dosage (0.9–6 g EPA+DHA/day), study duration (3–12 months), number of participants (a few dozen to several hundred), EPA-to-DHA ratio and supplement used (fish oil, borage oil, concentrated EPA). This heterogeneity makes precise dosage recommendations difficult.
Blinding and placebo
Many older fish oil studies had blinding problems: the typical fishy smell and taste can reveal treatment group allocation. More recent studies use odourless capsule formulations and better-matched placebos (e.g. olive oil).
Background medication
Most RA patients in studies were already taking DMARDs (such as methotrexate). Omega-3 was therefore investigated as an add-on to standard treatment. Extrapolation to untreated patients or other forms of arthritis is limited.
Spondyloarthritis, psoriatic arthritis and other forms of arthritis
The majority of high-quality studies relate to rheumatoid arthritis. For other inflammatory forms of arthritis such as psoriatic arthritis, ankylosing spondylitis or reactive arthritis, the evidence is considerably more limited. Some small studies suggest similar mechanisms — but robust meta-analyses are lacking.
In osteoarthritis (gonarthrosis, coxarthrosis), the evidence is mixed. Some studies show moderate pain reductions — the mechanisms, however, differ from those in RA (less inflammation inhibition, more cartilage-protective hypotheses). The Frontiers in Medicine (2025) meta-analysis on chronic pain also includes osteoarthritis patients and shows a moderate overall effect.
Dosage: what do studies show?
From RA studies, the following observations on dosage can be derived:
| EPA+DHA dose/day | Observation | Study basis |
|---|---|---|
| < 1.5 g/day | Little or no effects on RA endpoints | Several RCTs |
| 1.5–2.7 g/day | Variable results, partly significant | Several RCTs |
| ≥ 2.7 g/day (min. 3 months) | Significant pain reduction + NSAID sparing | Lee et al. 2012 (meta-analysis) |
| 3–6 g/day | Greatest effect in review analysis | Abdulrazaq et al. 2017 |
| Long-term intake ≥ 6 months | Increasing efficacy (SMD −0.83) | Frontiers in Medicine 2025 |
Detailed information on dosage recommendations can be found on the page Omega-3 daily dosage: what is reasonable?.
Omega-3 and biologics: compatible?
For RA patients on biologic therapy (TNF blockers such as adalimumab, etanercept or IL-6 inhibitors such as tocilizumab), no large interaction studies exist. Since omega-3 acts anti-inflammatorily via pathways different from biologics (fatty acid lipid membrane composition vs. direct cytokine blockade), the combination is theoretically reasonable and sometimes recommended in practice by rheumatologists. Before taking omega-3 supplements at higher doses, however, use should be discussed with the treating rheumatologist — especially if methotrexate or other immunomodulators are being used concurrently.
What do scientific societies say?
The European League Against Rheumatism (EULAR) has incorporated dietary aspects into its recommendations for RA treatment. Consumption of fish and omega-3-rich foods is described as a reasonable complementary measure. Several national rheumatology societies recommend the Mediterranean diet — naturally rich in omega-3 from fish and olive oil — as part of overall management.
Mediterranean diet and rheumatism
An analysis published in 2023 found that RA patients with high adherence to the Mediterranean diet had significantly lower inflammatory markers and better RA activity scores than patients with a Western dietary pattern. Omega-3 from fish is an essential component of the Mediterranean diet. The isolated effect of omega-3 is difficult to separate in observational dietary studies — but the association is plausible and consistent.
Practical assessment
The evidence on omega-3 in rheumatoid arthritis is consistent enough that many rheumatologists consider supplementation a reasonable complement to pharmacological treatment. Omega-3 cannot replace conventional medical treatment — but it can moderate symptoms such as joint pain and morning stiffness and possibly reduce NSAID requirements. Since joint complaints increase particularly with age, adequate omega-3 intake is especially relevant for older people — a comprehensive summary can be found in the article Omega-3 for older adults.
Patience is important: the effect does not appear immediately. Studies show effects are measurable after 3 months and more pronounced after 6 months. Taking omega-3 for a few weeks and then stopping prematurely due to "no effect" underestimates the temporal component of the effect.
More information on the underlying inflammatory mechanisms on the page Omega-3 and inflammation. On the role of omega-3 for the immune system, see the page Omega-3 and the immune system.
Frequently asked questions
Can I stop my rheumatism medication by taking omega-3?
No. Omega-3 is a complement to pharmacological therapy for RA, not a substitute. DMARDs such as methotrexate are crucial for controlling disease activity and preventing joint damage. Studies show that omega-3 can improve symptom control and reduce NSAID requirements — but cannot replace DMARDs or biologics. Any changes to medication must always be discussed with your treating rheumatologist.
What dose is reasonable for rheumatism?
Meta-analyses show the most consistent effects with doses of at least 2.7 g EPA+DHA per day for at least 3 months. Studies with 3–6 g/day showed the largest effects. Since omega-3 at this dose has no relevant side effects (except with anticoagulants), an intake of 2–4 g EPA+DHA per day, divided into 2 doses with meals, is a well study-supported protocol.
How long do I need to take omega-3 before noticing an effect?
Studies show that first measurable effects on joint pain can appear after 6–8 weeks. Clinically relevant and consistent improvements are typically seen after 3 months. The Frontiers in Medicine (2025) meta-analysis showed that effect size increased from SMD −0.27 at month 1 to SMD −0.83 at 6 months — long-term intake is therefore important.
Does omega-3 also help for osteoarthritis?
The evidence for osteoarthritis (gonarthrosis, coxarthrosis) is less consistent than for rheumatoid arthritis. Some studies show moderate pain reductions. The Frontiers in Medicine (2025) meta-analysis on chronic pain also included osteoarthritis patients and showed an overall SMD of −0.55. Since osteoarthritis has a different pathophysiology to RA (less inflammation, more cartilage degeneration), the mechanisms differ. However, supplementation may be useful for the inflammatory components of osteoarthritis.
Are there differences between fish oil and krill oil for rheumatism?
The evidence for krill oil in RA is much more limited than for fish oil. Krill oil contains EPA and DHA in phospholipid form, which may be more bioavailable than the triglyceride form of regular fish oil. No direct comparative study in RA patients exists. Most RA studies were conducted with fish oil in triglyceride or ethyl ester form. Specific data for krill oil are lacking for clear dosage statements in RA.
Interaction with anticoagulants and methotrexate
Omega-3 fatty acids have a mild antiplatelet effect. For RA patients taking methotrexate, leflunomide, corticosteroids or anticoagulants, omega-3 intake at higher doses (more than 3 g/day) should be coordinated with the rheumatologist. Intake of low to moderate doses (1–3 g/day) is considered safe and shows no relevant interactions with standard RA medications in clinical studies.
Medical disclaimer
This article is for general information purposes only and does not replace medical advice. All health statements are based on published scientific studies. Omega-3 supplements are food supplements and are not a substitute for a balanced diet or medical treatment. Rheumatoid arthritis is a serious condition requiring specialist medical diagnosis and treatment. Do not change your medication without consulting your doctor.